Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 169 of 5804
-
New combo therapy aims to extend life in advanced lung cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New biosimilar aims to match pertuzumab in breast cancer fight
Disease control OngoingThe trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Phase: PHASE3 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may h…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Cheap chemical could supercharge breast cancer radiation
Disease control Recruiting nowThis is a study aimed at testing a commonly available and inexpensive chemical (hydrogen peroxide) for efficacy in sensitising large cancerous lumps in the breast to a standard course of radiotherapy in patients with locally advanced or recurrent breast cancer. Laboratory researc…
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
Disease control CompletedBackground: More than 30,000 cases of human papillomavirus (HPV) associated cancers occur annually in the United States. When these cancers spread, they do not respond well to standard treatments and are often incurable. Researchers want to see if a mix of drugs can help. Objec…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Chemo-Free combo shows promise in CLL trial
Disease control CompletedThis study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale \[CIRS\]/score of ≤6 an…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may tell doctors when to add chemo to immunotherapy for lung cancer
Disease control Recruiting nowThe standard or usual treatment for this disease is pembrolizumab given by needle into the veins (IV). Some cancers shed DNA (circulating tumour DNA or ctDNA) or genes (biomarkers) into the blood, and levels of these biomarkers may be able to tell researchers how people respond …
Phase: PHASE2, PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo aims to stop prostate cancer spread after surgery
Disease control OngoingThis phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to stall breast cancer growth
Disease control OngoingPhase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therap…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Combination therapy aims to boost response in rare skin cancers
Disease control Recruiting nowThe purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of the combination therapy and to evaluate the safety and tolerability of the combination…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a chemo cocktail replace radiation for rectal cancer?
Disease control Recruiting nowMultimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard treatment of patients with stage II/III rectal cance…
Phase: PHASE3 • Sponsor: Yanhong Deng • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Ambulance crews test early antibiotics for sepsis
Disease control CompletedSepsis occurs when a serious infection - most commonly infection of the lungs, urinary system, or blood - leads to acute organ failure. It is a common, expensive, and frequently lethal condition. A growing body of evidence suggests that early recognition and treatment of sepsis c…
Phase: PHASE4 • Sponsor: Dr. Damon Scales • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for kids with rare cancers: targeted drug repotrectinib enters trial
Disease control Recruiting nowPhase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neur…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo shows promise in advanced lung cancer trial
Disease control CompletedThe purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with …
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill combo aims to wipe out breast tumors before surgery
Disease control OngoingThis is a prospective, open label, single-arm study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients
Phase: PHASE2, PHASE3 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows promise for kids with aggressive brain tumors
Disease control OngoingThis phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a blood thinner prevent strokes in brain bleed survivors?
Disease control Recruiting nowPrimary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with a…
Phase: PHASE3 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy aims to stop leukemia from coming back after transplant
Disease control Recruiting nowThis study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensi…
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse
Disease control OngoingChimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investig…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Drug combo aims to shrink Hard-to-Treat sarcomas
Disease control CompletedSoft tissue sarcoma is a relatively rare malignant tumor with an incidence of about 1-2/100,000. The best way to obtain evidence-based medical evidence is to participate in clinical trials with new drugs (especially targeted drugs and immunotherapy). Chidamide, an oral subtype-se…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC